Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 a Subfraction of LDL in Patients With Metabolic Syndrome.

• Status: Unknown status
• Trial end date: 2010-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is:

• To identify the common factor for L5 prevalence in patients with Metabolic Syndrome.

• To determine whether Ezetimibe, Simvastatin, and Vytorin can correct the L5- promoting factor and reduce L5 in Metabolic Syndrome patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Baylor College of Medicine
• Collaborator: Merck Sharp & Dohme Corp.
• Treatments: Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Simvastatin

Criteria

Inclusion Criteria:

• Participants who meet 3 or more of the 5 criteria specified in the ATPIII guidelines will be recruited.

• The 5 criteria are:

1. abdominal obesity (men>40 inches, women >35 inches);

2. TG> 150mg/dL;

3. low HDL-C (men < 40mg/dL, women < 50 mg/dL);

4. high blood pressure (>or=130/>or=85 mmHg);

5. fasting glucose > or = 110mg/dL.

• People with different ethnic backgrounds will be included.

Exclusion Criteria:

• symptomatic coronary artery disease

• peripheral vascular disease

• cerebral ischemia (stroke)

• smoking

• hypothyroidism

• kidney diseases

• consumption of antioxidation supplements/drugs or use of lipid-lowering drugs in the last 3 months

• women who are pregnant, nursing, or planning to become pregnant